Home » Migraine Study Does Not Meet Primary Endpoint
Migraine Study Does Not Meet Primary Endpoint
Alexza Pharmaceuticals, Inc. announced preliminary results from its 366 patient Phase IIb clinical trial of AZ-104 in patients with migraine headache.
StreetInsider
StreetInsider
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May